Brean Capital maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $35.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Cantor Fitzgerald Cuts Price Target on Celldex (CLDX) to $31 Following Rintega Filing Delay August 11, 2015 10:10 AM Roth Capital Trims PT on Celldex (CLDX) to $39 Following Q2 Results; Would be Buyers on WeaknessAugust 11, 2015 8:11 AM Cowen Cuts Price Target on Celldex (CLDX) Following 2Q and Clinical Update August 11, 2015 6:58 AM Celldex (CLDX) Reports Q2 Loss of $0.33August 10, 2015 4:51 PM Celldex Reports Second Quarter 2015 ResultsAugust 10, 2015 4:01 PM